Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,576.76
(
-0.06%
)
US TECH 100
23,422.80
(
-0.41%
)
Dow Jones
46,278.62
(
0.15%
)
Brent Oil
100.31
(
3.63%
)
Bitcoin
69,500.00
(
-1.97%
)
News Focus
News Focus
Post# of 257275
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122807
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 225249

Wednesday, 10/02/2019 7:10:56 PM

Wednesday, October 02, 2019 7:10:56 PM

Post# of 257275
SVRA -58% on FDA rebuff:

https://finance.yahoo.com/news/savara-announces-fda-response-type-120200975.html

In the written response received by Savara on October 1, the FDA indicated that the data provided in the briefing package do not provide sufficient evidence of efficacy and safety and did not recommend that the Company submit a Biologics License Application (BLA). The Company is working to determine the next steps for the Molgradex development program.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today